• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 31 Mar

    Opus Genetics Announces Financial Results for Full Year 2024

    Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash position with $21.5 million financing to supplement $30.3 million year-end balance New capital supports delivery on key milestones for two lead gene therapy candidates OPGx-LCA5 and OPGx-BEST1 RESEARCH TRIANGLE PARK,… Read More..

    Share this:
  • 31 Mar

    Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

    BROOMFIELD, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today provided a corporate update on its strengthened positioning following… Read More..

    Share this:
  • 31 Mar

    BioStem Announces Notice of Allowance for Two U.S. Patent Applications

    POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two… Read More..

    Share this:
« Previous 1 … 32 33 34 35 36 … 257 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact